Atossa Therapeutics, Inc. (ATOS) - Form 8-K Summary
Business Context and Reporting Period
Atossa Therapeutics, Inc., a Delaware corporation, filed this Current Report on Form 8-K on August 7, 2026. The filing announces the release of financial results for the second quarter ended June 30, 2026, and provides a company update. The company's common stock trades on the Nasdaq Capital Market under the symbol ATOS.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K document.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the text provided. Investors must refer to the attached press release (Exhibit 99.1) for comparative financial analysis.
Guidance, Outlook, and Risks
The company issued a press release on August 7, 2026, containing a company update. The 8-K text does not include specific guidance, outlook figures, management commentary, or risk factors. The filing explicitly states that the information in Items 2.02 and 9.01, including the press release, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other SEC filings.
Key Facts for Investor Verification
- Verify the specific Q2 2026 financial results (revenue, net loss, cash position) in the attached Exhibit 99.1 press release.
- Confirm the company's cash runway and burn rate as disclosed in the full press release.
- Review the "Company Update" section of the press release for any new clinical trial data or regulatory milestones.
- Note that the financial information in this 8-K is not subject to the liabilities of Section 18 of the Exchange Act.